Holen Sie sich die Stockscreener-App
2.05
3.54%
0.07
Vorhandelsmarkt:
2.06
0.01
+0.49%
Allogene Therapeutics Inc Aktie (ALLO) Neueste Nachrichten
Citizens reiterates Allogene stock rating on trial progress By Investing.com - Investing.com India
Walleye Capital LLC Invests $6.80 Million in Allogene Therapeutics, Inc. $ALLO - MarketBeat
Allogene Therapeutics (ALLO): Frazier funds disclose 5.6% ownership and affiliated stakes - Stock Titan
Allogene Therapeutics (ALLO) Income Statement & Earnings - moomoo.com
Clinical: FDA Accelerates Allogene's TALEN-Edited Lymphoma Cell Therapy - CRISPR Medicine News
State Street Corp Expands Allogene Therapeutics (ALLO) Stake with Strategic Share Purchase - GuruFocus
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs - The Globe and Mail
A Quick Look at Today's Ratings for Allogene Therapeutics(ALLO.US), With a Forecast Between $9 to $14 - moomoo.com
Piper Sandler Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $10 - moomoo.com
Allogene Therapeutics Remains Attractive Given Valuation, Clinical Strategy, RBC Says - marketscreener.com
TD Cowen Maintains Allogene Therapeutics(ALLO.US) With Buy Rating - moomoo.com
Allogene Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
722,928 Shares in Allogene Therapeutics, Inc. $ALLO Acquired by Hennion & Walsh Asset Management Inc. - MarketBeat
Allogene Therapeutics earnings beat by $0.04, revenue topped estimates - Investing.com Canada
Allogene Therapeutics Inc (ALLO) (Q2 2026) Earnings Call Highlights: RMAT Designation and Rapid ... - Yahoo Finance
Allogene Therapeutics Inc (ALLO) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Allogene Therapeutics (ALLO) Advances Clinical Pipeline Amidst H - GuruFocus
Allogene Therapeutics: Q2 Earnings Snapshot - AOL.com
Allogene Therapeutics Q2 2026: EPS beats, cash extends to 2029 - scanx.trade
Transcript : Allogene Therapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026 - marketscreener.com
Allogene Therapeutics Announces Q2 2026 Financial Results Highlighting Reduced Losses, First Collaboration Revenue, and Significant Equity Raise - Kalkine Media
Earnings call transcript: Allogene Therapeutics beats Q2 2026 EPS forecast By Investing.com - Investing.com Canada
Allogene Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Allogene Therapeutics Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: Allogene Therapeutics beats Q2 2026 EPS forecast - Investing.com
Allogene TherapeuticsMay Offer Up To $500 Million In Securities - TradingView
Allogene Therapeutics Q2 Loss Narrows - marketscreener.com
Allogene Therapeutics (NASDAQ:ALLO) Issues Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Earnings Flash (ALLO) Allogene Therapeutics Posts Q2 Loss $0.13 per Share, vs. FactSet Est of $0.17 Loss - marketscreener.com
Allogene posts $42.7 million Q2 loss as cash reaches $423.6 million - Quiver Quantitative
Allogene Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
ALLO: ALPHA3 interim results highlight cema-cel's promise in LBCL and strong financial runway - TradingView
Allogene Therapeutics, Inc. Announces Cemacabtagene Ansegedleucel (Cema-Cel) Is Being Evaluated in Alpha3, the First Pivotal, Randomized Phase 2 Trial in LBCL - marketscreener.com
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update - GlobeNewswire
Allogene Therapeutics Inc (ALLO) Q2 2026 Earnings Report Preview: What To Look For - Yahoo Finance
Allogene Therapeutics (ALLO) Short Interest & Short Float | Updated Aug 2026 $ALLO - MarketBeat
Allogene Therapeutics, Inc. expected to post a loss of 17 cents a shareEarnings Preview - TradingView
Allogene Therapeutics (ALLO) stake: Belldegrun group reports 3.9% ownership - Stock Titan
State Street Corporation (ALLO) discloses 5.5% beneficial stake in Allogene - Stock Titan
Allogene Therapeutics (ALLO) Institutional Ownership 2026 $ALLO - MarketBeat
Allogene Therapeutics, Inc. (ALLO) Options Chain - Yahoo Finance
Allogene Therapeutics (ALLO) Expected to Release Quarterly Earnings on Wednesday - MarketBeat
William Blair Maintains Allogene Therapeutics(ALLO.US) With Buy Rating - Moomoo
Allogene Therapeutics Q2 Results: Earnings Call Set for Aug 12 - scanx.trade
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update - The Manila Times
Allogene sets Aug. 12 update on cancer and autoimmune disease - Stock Titan
Analysts’ Top Healthcare Picks: Repligen (RGEN), Allogene Therapeutics (ALLO) - The Globe and Mail
$Allogene Therapeutics (ALLO.US)$ Praise be to God - Moomoo
Allogene Therapeutics (ALLO) Stock Gains on FDA RMAT and Fast Tr - GuruFocus
Allogene Therapeutics stock rises on FDA regulatory designations By Investing.com - Investing.com South Africa
Allogene Therapeutics (ALLO) Gains FDA RMAT and Fast Track Desig - GuruFocus
Allogene Therapeutics, Inc. Receives FDA Regenerative Medicine Advanced Therapy And Fast Track Designations For Cemacabtagene Ansegedleucel As First-Line Consolidation Therapy For Large B-Cell Lymphoma - marketscreener.com
Allogene Therapeutics Receives FDA Regenerative Medicine - GlobeNewswire
Insider Sellers Might Regret Selling Allogene Therapeutics Shares at a Lower Price Than Current Market Value - simplywall.st
Allogene Therapeutics Inc (ALLO) Cash Flow - TradingKey
Allogene Therapeutics (NASDAQ:ALLO) Shares Up 9.5%Should You Buy? - MarketBeat
ALLO|Allogene Therapeutics Inc|Price:1.740|Chg%:-0.080 - TradingKey
Allogene Therapeutics Inc (ALLO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Allogene Therapeutics, Inc. Revenue Breakdown – NASDAQ:ALLO - TradingView
ALLO Stock Hits 2-Year Highs – Analyst Calls Allogene’s Phase 2 Trial Data To Treat Lymphoma A ‘Home Run’ - Stocktwits
Allogene Therapeutics, Inc. Stock 12‑Month Price Target Cut to $8.75, Implies 381% Upside - TradingView
Analysts Are Bullish on Top Healthcare Stocks: Tenax Therapeutics (TENX), Allogene Therapeutics (ALLO) - The Globe and Mail
Allogene reports 31% response rate in renal cancer trial By Investing.com - Investing.com South Africa
Allogene Therapeutics (ALLO) Unveils Promising Phase 1 Study Res - GuruFocus
Allogene reports 31% response rate in renal cancer trial - Investing.com
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors - The Manila Times
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):